Advertisement

Neuromuskuläre Erkrankungen

  • W. Müller Felber
  • M. Damian
  • R. Stingele
  • H.-C. Hansen

Zusammenfassung

Akute toxische nekrotisierende Myopathien können durch eine Vielzahl physikalischer und chemischer Noxen induziert werden. Da die resultierenden Mus-kelgewebenekrosen (Rhabdomyolysen) potentiell lebensbedrohliche Komplikationen erzeugen können (Übersicht 39-1), ist in der Regel eine vorübergehende Intensivüberwachung, gelegentlich auch eine eingreifende Intensivtherapie erforderlich. Die Langzeitprognose ist nach überstandener Akutphase sehr gut.

Abkürzungen

AZT

Azidothymidin = Zidovudin

CK

Creatinkinase

COX

Cytochrom-c-Oxidase

CPT

Carnitin-Palmityltransferase

DM

Dermatomyositis

GAD

Glutamat-Decarboxylase

MAD

multiple Acyl-CoA-dehydrogenase

MADA

Myoadenylat-Deaminase

MELAS

mitochondriale Enzephalomyopathie mit Laktatazidose und schlaganfallähnlichen Episoden

MERRF

Myoklonusepilepsie mit „ragged red fibers“

MH

maligne Hyperthermie

MRT

Magnetresonanztomographie

mtDNA

mitochondriale DNA

PM

Polymyositis

VLCAD

„very long-chain acyl-CoA-dehydrogenase“

TFP

trifunktionelles Protein der β-Oxidation

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

Zu Unterkap. 1: „Rhabdomyolyse“

  1. Bolton CF (1996) Sepsis and the systemic inflammatory response syndrome: neuromuscular manifestations. Crit Care Med 24:1408–1416.CrossRefPubMedGoogle Scholar
  2. Klockgether T, Weiler M, Haarmeir T, Kaskas B, Maier G, Dichgans J (1997) Gluteal compartment syndrome due to rhabdomyolysis after heroin abuse. Neurology 48:275–276.CrossRefPubMedGoogle Scholar
  3. Ramsay DA, Zochodne DW, Robertson DM, Nag S, Ludwin SK (1993) A syndrome of acute severe muscle necrosis in intensive care unit patients. J Neuropathol Exp Neurol 52:387–398.CrossRefPubMedGoogle Scholar
  4. Rich MM, Teener JW, Raps EC, Schotland MD, Bird SJ (1996) Muscle is electrically inexcitable in acute quadriplegic myopathy. Neurology 46:731–736.CrossRefPubMedGoogle Scholar
  5. Winkler G, Beese M (1998) Rhabdomyolysen. In: Beese M, Winkler G (Hrsg) MRT der Muskulatur. Thieme, Stuttgart, S 247–256.Google Scholar

Zu Unterkap. 2: „Maligne Hyperthermie“

  1. Allen GC (1993) Malignant hyperthermia and associated disorders. Curr Opin Rheumatol 5/6:719–724.CrossRefPubMedGoogle Scholar
  2. Larsen UT, Juhl B, Hein Sorensen O, Fine Olivarius B de (1989) Complications during anaesthesia in patients with Duchenne’s muscular dystrophy (a retrospective study) [see comments]. Can J Anaesth 36/4:418–422.CrossRefPubMedGoogle Scholar
  3. Lynch PJ, Krivosic Horber R, Reyford H et al. (1997) Identification of heterozygous and homozygous individuals with the novel RYR1 mutation Cys35Arg in a large kindred [see comments]. Anesthesiology 86/3:620–626.CrossRefPubMedGoogle Scholar
  4. Manning BM, Quane KA, Ording H et al. (1998) Identification of novel mutations in the ryanodine-receptor gene (RYR1) in malignant hyperthermia: genotype-phenotype correlation. Am J Hum Genet 62/3:599–609.CrossRefPubMedPubMedCentralGoogle Scholar
  5. Mortier W, Breucking E (1993) Diagnosis of malignant hyperthermia susceptibility. 1. The significance of in vitro susceptibility tests. Anästhesist 42/10:675–683.Google Scholar
  6. Ogawa Y (1994) Role of ryanodine receptors. Crit Rev Biochem Mol Biol 29/4:229–274.CrossRefPubMedGoogle Scholar
  7. Wedel DJ (1992) Malignant hyperthermia and neuromuscular disease. Neuromuscul Disord 2/3:157–164.CrossRefPubMedGoogle Scholar
  8. Weglinski MR, Wedel DJ, Engel AG (1997) Malignant hyperthermia testing in patients with persistently increased serum creatine kinase levels. Anesth Analg 84/5:1038–1041.CrossRefPubMedGoogle Scholar

Zu Unterkap. 3: „Myositith“

  1. Brook I (1996) Pyomyositis in children, caused by anaerobic bacteria. J Pediatr Surg 31/3:394–396.CrossRefPubMedGoogle Scholar
  2. Cohen R, Lipper S, Dantzker DR (1993) Inclusion body myositis as a cause of respiratory failure. Chest 104/3:975–977.CrossRefPubMedGoogle Scholar
  3. Dalakas MC, Illa I, Dambrosia JM et al. (1993) A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis [see comments]. N Engl J Med 329/27:1993–2000.CrossRefPubMedGoogle Scholar
  4. Dalakas MC (1995) Update on the use of intravenous immune globulin in the treatment of patients with inflammatory muscle disease. J Clin Immunol 15 [Suppl 6]:70 S–75 S.CrossRefGoogle Scholar
  5. Dougenis D, Papathanasopoulos PG, Paschalis C, Papapetropoulos T (1996) Spontaneous esophageal rupture in adult dermatomyositis. Eur J Cardiothorac Surg 10/11:1021–1023.CrossRefPubMedGoogle Scholar
  6. Harmon KR, Leatherman JW (1988) Respiratory manifestations of connective tissue disease. Semin Respir Infect 3/3:258–273.PubMedGoogle Scholar
  7. Mastaglia FL, Phillips BA, Zilko P (1997) Treatment of inflammatory myopathies. Muscle Nerve 20/6:651–664.CrossRefPubMedGoogle Scholar
  8. Patel SR, Olenginski TP, Perruquet JL, Harrington TM (1997) Pyomyositis: clinical features and predisposing conditions. J Rheumatol 24/9:1734–1738.PubMedGoogle Scholar
  9. Reimers CD, Finkenstaedt M (1997) Muscle imaging in inflammatory myopathies. Curr Opin Rheumatol 9/6:475–485.CrossRefPubMedGoogle Scholar
  10. Remig J, Froscher W (1987) Acute trichinosis. 193 cases in an epidemic. Dtsch Med Wo-chenschr 112/48:1855–1859.CrossRefGoogle Scholar
  11. Villalba L, Hicks JE, Adams EM et al. (1998) Treatment of refractory myositis: a randomized crossover study of two new cytotoxic regimens. Arthritis Rheum 41/3:392–399.CrossRefPubMedGoogle Scholar
  12. Wolf JE and Rabinowitz LG (1995) Streptococcal toxic shock-like syndrome. Arch Dermatol 131/1:73–77.CrossRefPubMedGoogle Scholar

Zu Unterkap. 4: „Metabolische Myopathien“

  1. Damian MS, Seibel P, Reichmann H et al. (1995) Clinical spectrum of the MELAS mutation in a large German family. Acta Neurol Scand 92:409–415.CrossRefPubMedGoogle Scholar
  2. El-Schahawi A, Bruno C, Tsujino S et al. (1997) Sudden infant death syndrome (SIDS) in a family with myophosphorylase deficiency. Neuromusc Dis 7:81–83.CrossRefPubMedGoogle Scholar
  3. Ricker K (1997) Rolle von Ionenkanälen für die Therapie in der Neurologie. Akt Neurol 24:90–92.CrossRefGoogle Scholar
  4. Showalter CJ, Engel AG (1997) Acute quadriplegic myopathy: analysis of myosin isoforms and evidence for calpain-mediated proteolysis. Muscle Nerve 20:316–322.CrossRefPubMedGoogle Scholar
  5. Schäfer J, Reichmann H (1998) Betaoxidationsdefekte und Lipidspeicherkrankheiten. In: Hopf HC, Deuschl, Diener, Reichmann (Hrsg) Neurologie in Praxis und Klinik. Thieme, Stuttgart.Google Scholar
  6. Wokke JHJ, Ausems MGEM, van den Boogaard M-JH et al. (1995) Genotype-phenotype correlation in adult-onset acid maltase deficiency. Ann Neurol 38:450–454.CrossRefPubMedGoogle Scholar
  7. Zeviani M, Gellera C, Antozzi C et al. (1991) Maternally inherited myopathy and cardio-myopathy: association with mutation in mitochondrial DNA tRNA Leu(UUR). Lancet 338:143–147.CrossRefPubMedGoogle Scholar
  8. Zierz S (1998) Gykogenstoffwechselerkrankungen. In: Hopf HC et al. (Hrsg) Neurologie in Praxis und Klinik. Thieme, Stuttgart.Google Scholar

Zu Unterkap. 5: „Stiff-man-Syndrom“

  1. Folli F, Solimena M, Cofiell R et al. (1993) Autoantibodies to a 128-kd synaptic protein in three women with the stiff-man syndrome and breast cancer. N Engl J Med 328:546–551.CrossRefPubMedGoogle Scholar
  2. Meinck HM, Ricker K, Hülser PJ et al. (1994) Stiff man syndrome: clinical and laboratory findings in eight patients. J Neurol 241:157–166.CrossRefPubMedGoogle Scholar
  3. Meinck HM, Ricker K, Hülser PJ, Solimena M (1995) Stiff man syndrome: neurophysiologi-cal findings in eight patients. JNeurol 242:134–142.Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1999

Authors and Affiliations

  • W. Müller Felber
  • M. Damian
  • R. Stingele
  • H.-C. Hansen

There are no affiliations available

Personalised recommendations